Intellect Neurosciences, Inc. Receives New Patent on Clinical Stage Drug from the Israeli Patent and Trademark Office
NEW YORK — Intellect Neurosciences, Inc. , a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the Alzheimer’s disease and other serious neurodegenerative conditions today announced it has received a new patent from the Israeli Patent and Trademark Office related to OX1, the Company’s clinical-stage drug candidate.

Read more on GlobeNewswire via Yahoo! Finance

Brand and Trademark Infringement in Global Sports Draw Red Card From CMO Council
Chief Marketing Officer (CMO) Council Developing Thought Leadership Initiative to Help Brand Sponsors and Sports Franchises Secure the Trust of Their Brands

Read more on Marketwire